On Monday 9th of June, Dr Nat Hastings presented the developments and plans of Cellestial Health at the annual #BioSeed event, where pitches are delivered by companies looking for Seed funding.
At the moment, Cellestial is only preparing for its Seed funding round. What are the benefits of our early discussion with the investor community?
We are inviting investors to provide feedback on our Pre-Seed milestones, in essence becoming 𝗽𝗮𝗿𝘁𝗻𝗲𝗿𝘀 to help us shape our journey – even before, or even 𝘸𝘪𝘵𝘩𝘰𝘶𝘵 becoming a part of the cap table. We are building relationships and raising awareness, and your input is valuable.
Do get in touch with our team to learn more and start exploring synergies.
PS: It was good to see Claudio Dagostin of o2h discovery and catch up with Nick Sireau, the CEO of Serenatis Bio; both Serenatis and Cellestial are advancing their neurological drug pipelines supported by the o2h kickstarter award.
